• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

    7/31/24 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELUT alert in real time by email

    SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries.

    "We are pleased to welcome Ryan to the Elutia CRU as our new Vice President of Operations," said Dr. Randy Mills, Elutia's Chief Executive Officer. "At Elutia, culture matters, and Ryan has both the experience and character to make him an excellent fit and an effective leader within our growing organization. His extensive operational and manufacturing expertise across both pharma and devices will be instrumental as we launch EluPro®, the world's first FDA-cleared antibiotic-eluting BioEnvelope, in the second half of 2024."

    Prior to joining Elutia, Dr. Marques served as the Head of U.S. Operations at Nobelpharma America, a pharmaceutical and medical device company dedicated to treating rare and neglected diseases. Before that, he led operations at Next Breath Inc./Aptar Pharma, a contract services provider for pharmaceutical, biotech, and medical device companies, as well as at Canon BioMedical, a medical diagnostics company. Dr. Marques began his industry career by managing manufacturing and technical operations at QIAGEN. Dr. Marques completed his post-doctoral training at the University of Maryland (Center for Vaccine Development) and holds a Ph.D. in Molecular Microbiology and Immunology and an MBA from the Robert H. Smith School of Business, University of Maryland.

    "I am honored to join Elutia at such an important time for the Company," said Dr. Marques. "I am excited to be working as part of the talented Elutia team as we launch EluPro and expand our production capacity for the current product offerings as well as new drug-eluting biomatrix products in development."

    About Elutia

    Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia's mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

    Forward-Looking Statements

    This press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the launch of EluPro, expansion of production capacity and new product development. These statements are based on the Company's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements here due to changes in economic, business, competitive or regulatory factors, and other risks and uncertainties, including those set forth in the Company's filings with the SEC under the heading "Risk Factors". The forward-looking statements in this press release speak only as of the date of this press release. The Company does not undertake any obligation to update or revise these forward-looking statements for any reason, except as required by law.

    Investors:

    Matt Steinberg

    FINN Partners

    [email protected]



    Primary Logo

    Get the next $ELUT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ELUT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELUT
    SEC Filings

    See more
    • Elutia Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ELUTIA INC. (0001708527) (Filer)

      6/4/25 5:00:15 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Elutia Inc.

      SCHEDULE 13G/A - ELUTIA INC. (0001708527) (Subject)

      5/15/25 4:49:05 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Elutia Inc.

      SCHEDULE 13G - ELUTIA INC. (0001708527) (Subject)

      5/15/25 4:25:26 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices

      — The EluPro BioEnvelope findings demonstrate the bioactive properties and superior healing response compared to synthetic materials for cardiac implantable electronic devices (CIEDs) — GAITHERSBURG, Md., July 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a new study describing the bioinductive effects of its antibiotic-eluting CIED biologic envelope in the Journal of Functional Biomaterials. Researchers from the Department of Cardiac Sciences at the Cumming School of Medicine found that the biomatrix in EluPro controlled inflammation and supported vascularization, ke

      7/1/25 8:00:00 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards

      Recognition highlights EluPro™ Antibiotic-Eluting BioEnvelope's impact on device protection for cardiac implantable electronic devices (CIEDs) and neurostimulators SILVER SPRING, Md., June 26, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, has been recognized with two prestigious honors—Innovation and Product Launches—in the 2025 Medical Device Network Excellence Awards. The awards celebrate Elutia's advancements in drug eluting bioenvelopes and the successful commercial introduction of EluPro. "We're honored to receive recognition from Medical Device Network in both the Innovation and Product Launch

      6/26/25 8:00:00 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method

      SILVER SPRING, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the publication of a peer-reviewed article describing the first validated method for measuring antibiotic release from a biologic envelope. The novel method demonstrates in vitro elution that closely replicates preclinical studies, offering an approach to characterize drug release while enabling faster, lower cost development and testing of the EluPro portfolio. The article appears in the current issue of Dissolution Technologies. Drug release testing is a critical element of product development and regulatory evaluat

      5/28/25 8:00:00 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:30:13 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Highcape Capital, L.P. bought $1,050,000 worth of shares (420,000 units at $2.50) (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      3/13/25 4:28:27 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Birchview Capital, Lp bought $206,958 worth of shares (140,000 units at $1.48) (SEC Form 4) (Amendment)

      4/A - ELUTIA INC. (0001708527) (Issuer)

      2/20/24 12:27:11 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Mills C Randal converted options into 22,473 shares and covered exercise/tax liability with 8,019 shares, increasing direct ownership by 5% to 321,167 units (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      6/24/25 5:00:06 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 12,500 shares and covered exercise/tax liability with 4,461 shares, increasing direct ownership by 2% to 350,417 units (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      6/12/25 5:00:16 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PRESIDENT AND CEO Mills C Randal converted options into 27,084 shares and covered exercise/tax liability with 9,664 shares, increasing direct ownership by 6% to 306,713 units (SEC Form 4)

      4 - ELUTIA INC. (0001708527) (Issuer)

      6/12/25 5:00:09 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Financials

    Live finance-specific insights

    See more
    • Elutia to Report First Quarter 2025 Financial Results on Thursday, May 8, 2025

      SILVER SPRING, Md., May 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its first quarter 2025 financial results after market close on Thursday, May 8, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13753035 Please log in approximately 10 minutes prior to the scheduled start time. A liv

      5/1/25 8:00:00 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025

      SILVER SPRING, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter and full year 2024 financial results after market close on Thursday, March 6, 2025. Members of the Company's management team will host a conference call and webcast starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click hereU.S. Investors: 877-407-8029International Investors: 201-689-8029Conference ID: 13751810 Please log in approximately 10 minutes prior to the scheduled

      2/20/25 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025

      Over 100 EluPro VAC Submissions and 19% SimpliDerm Growth Drive Momentum into 2025 SILVER SPRING, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today provided a business update and financial results for the third quarter ended September 30, 2024. Business Highlights: First Commercial Use: Announced the first patient implant of EluPro, the FDA-cleared antibiotic-eluting biologic envelope for pacemakers and neurostimulators.Strong Initial Adoption: EluPro is being utilized across all major cardiac implantable electronic device (CIED) brands and in neurostimulation procedures. EluPro now accounts

      11/14/24 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Leadership Updates

    Live Leadership Updates

    See more
    • Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

      SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia"), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries. "We are pleased to welcome Ryan to the Elutia CRU as our new Vice President of Operations," said Dr. Randy Mills, Elutia's Chief Executive Officer. "At Elutia, culture matters, and Ryan has both the experience and character to make him an excellent fit and an effectiv

      7/31/24 4:05:00 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Elutia Inc.

      SC 13G - ELUTIA INC. (0001708527) (Subject)

      10/15/24 6:59:31 AM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Elutia Inc. (Amendment)

      SC 13G/A - ELUTIA INC. (0001708527) (Subject)

      2/20/24 12:03:03 PM ET
      $ELUT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care